RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DANESI R
Collezione AO Ordine Mauriziano

Items : 4

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.

2023
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2022 Sep 21;12:979519. doi: 10.3389/fonc.2022.979519. eCollection 2022.

2022
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Implications of KRAS mutations in acquired resistance to treatment in NSCLC. in Oncotarget / Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19.

2018
AO Ordine Mauriziano

Del Re M; Rofi E; Restante G; Crucitta S; Arrigoni E; Fogli S; Di Maio M; Petrini I; Danesi R;

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. in Oncotarget / Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

2017
AO Ordine Mauriziano

Galimberti S; Bucelli C; Arrigoni E; Baratè C; Grassi S; Ricci F; Guerrini F; Ciabatti E; Fava C; D'Avolio A; Fontanelli G; Cambrin GR; Isidori A; Loscocco F; Caocci G; Greco M; Bocchia M; Aprile L; Gozzini A; Scappini B; Cattaneo D; Scortechini AR; La Nasa G; Bosi A; Leoni P; Danesi R; Saglio G; Visani G; Cortelezzi A; et alii...